Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous administration of Tysabri rather than IV, citing shorter duration of delivery and ...
When deciding whether to use subcutaneous (SubQ) or intravenous (IV) therapies, clinicians must weigh several clinical and practical factors. One of the first considerations is the type of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback